Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Short term Debt (2016 - 2025)

Guided Therapeutics' Short term Debt history spans 13 years, with the latest figure at $37000.0 for Q4 2025.

  • On a quarterly basis, Short term Debt fell 68.64% to $37000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $37000.0, a 68.64% decrease, with the full-year FY2025 number at $37000.0, down 68.64% from a year prior.
  • Short term Debt hit $37000.0 in Q4 2025 for Guided Therapeutics, down from $79000.0 in the prior quarter.
  • Over the last five years, Short term Debt for GTHP hit a ceiling of $1.1 million in Q2 2024 and a floor of $17000.0 in Q4 2022.
  • Historically, Short term Debt has averaged $211933.3 across 4 years, with a median of $60000.0 in 2025.
  • Biggest five-year swings in Short term Debt: skyrocketed 77.78% in 2022 and later crashed 94.69% in 2025.
  • Tracing GTHP's Short term Debt over 4 years: stood at $88000.0 in 2021, then tumbled by 80.68% to $17000.0 in 2022, then soared by 594.12% to $118000.0 in 2024, then tumbled by 68.64% to $37000.0 in 2025.
  • Business Quant data shows Short term Debt for GTHP at $37000.0 in Q4 2025, $79000.0 in Q3 2025, and $60000.0 in Q2 2025.